Skip to main content
Premium Trial:

Request an Annual Quote

BTIG Initiates Coverage of Berkeley Lights With Buy Rating

NEW YORK – BTIG said on Tuesday it has initiated coverage of Berkeley Lights with a Buy rating and a $70 per share price target.

In a note to investors, BTIG's Mark Massaro said that the Emeryville, California-based firm is emerging as a leader in aiding researchers characterize live cells for accelerating development of biotherapeutics and other cell-based products.

Berkeley Light's platform functionally screens and recovers individual cells for antibody discovery, cell line development, T-cell analysis, and synthetic biology. Its flagship Beacon instrument analyzes live cells by leveraging its proprietary OptoElectro Positioning technology.

Massaro valued the potential market for Berkeley Lights at nearly $25 billion. In contrast to current methods, Berkeley's platform "weeds out" poorly performing cells early on in its workflow, he wrote, allowing for the growth of the best cell candidates, saving time and millions of dollars in costs.

"We believe [Berkeley Lights] can displace a number of fragmented lab methods and consolidate the workflow for the cell-based products market with its Beacon and Lightning platforms," he wrote, adding that the firm's "'razor/razorblade' platforms enable researchers access to single-cell-specific digital information and provides a means for identifying and isolating the best cells used to develop the best therapies to the market much faster and a lot cheaper."

In addition, Berkeley Lights' academic and commercial partnerships "position [the firm] for success as the growing interest in cell-based products gains traction and visibility," he wrote. Customers are also able to access Berkeley Lights' platform through direct purchase or subscription or through a strategic partnership.

In morning trading on the Nasdaq, shares of Berkeley Lights were down 1 percent at $48.64.

The company said last month that it will launch a subscription-based model for its optoelectronic cell analysis platforms.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.